Real-world experience with pacritinib for patients with myelofibrosis refractory to ruxolitinib: a report of three cases
{{output}}
Objectives: Ruxolitinib, a Janus kinase (JAK) inhibitor, can lead to severe ruxolitinib discontinuation syndrome (RDS) upon abrupt cessation in myelofibrosis (MF). Pacritinib, a selective JAK2/IRAK1 inhibitor with minimal JAK1 in... ...
